🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Daniel H. Shevrin

Endeavor Health

ORCID: 0000-0001-8426-8888
Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE)”.

Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE)

European Urology Focus(2023)10.1016/j.euf.2023.06.006
N/A
0.587DataRank · unranked
49 citations

Xiangying Chu, Noah M. Hahn, Eugene J. Pietzak, Angela B. Smith, Daniel H. Shevrin +9 more

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

European Urology Open Science(2021)10.1016/j.euros.2021.09.015
N/A
0.449DataRank · unranked
19 citations

Emmanuel S. Antonarakis, Tina Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan +22 more

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial

Annals of Oncology(2025)10.1016/j.annonc.2025.08.004
N/A
0.345DataRank · unranked
9 citations

Y. Chen, David F. Jarrard, Jorge A. García, R. Dreicer, Guoqiang Liu +12 more

Phase III study of local or systemic therapy INtensification DIrected by PET in prostate CAncer patients with post-prostaTEctomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps5098
N/A
0.208DataRank · unranked
3 citations

Yu‐Hui Chen, Steve Y. Cho, Fenghai Duan, Christos E. Kyriakopoulos, Daniel H. Shevrin +10 more

PET-directed local or systemic therapy intensification in prostate cancer patients with post-prostatectomy biochemical recurrence: A trial of the ECOG-ACRIN Cancer Research Group (EA8191).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.tps267
N/A
0.165DataRank · unranked
2 citations

Yu‐Hui Chen, Steve Y. Cho, Fenghai Duan, Christos E. Kyriakopoulos, Daniel H. Shevrin +10 more

Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps5118
N/A
0.104DataRank · unranked
1 citations

Yu‐Hui Chen, Steve Y. Cho, Fenghai Duan, Christos E. Kyriakopoulos, Alicia K. Morgans +10 more

Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.tps402
N/A
0DataRank · unranked
0 citations

Yu‐Hui Chen, Steve Y. Cho, Fenghai Duan, Christos E. Kyriakopoulos, Alicia K. Morgans +10 more